Production of salbutamol sulfate for inhalation by high-gravity controlled antisolvent precipitation

被引:66
作者
Chiou, Herbert
Li, Li
Hu, Tingting
Chan, Hak-Kim [1 ]
Chen, Jian-Feng
Yun, Jimmy
机构
[1] Univ Sydney, Fac Pharm A15, Sydney, NSW 2006, Australia
[2] Beijing Univ Chem Technol, Key Lab Nanomat, Beijing 100029, Peoples R China
[3] NanoMat Technol Pte Ltd, Singapore 139959, Singapore
基金
美国国家科学基金会; 澳大利亚研究理事会;
关键词
salbutamol sulfate; high gravity controlled precipitation; antisolvent crystallisation; inhalation drug delivery; rotating packed bed;
D O I
10.1016/j.ijpharm.2006.09.022
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
The purpose of this study was to produce salbutamol sulfate (SS) as a model anti-asthmatic drug using high-gravity controlled precipitation (HGCP) through antisolvent crystallisation. An aqueous solution of SS was passed through a HGCP reactor with isopropanol as antisolvent to induce precipitation. Spray drying was employed to obtain dry powders. Scanning electron microscopy, X-ray powder diffraction (XRD), density measurement, thermal gravimetric analysis, and dynamic vapour sorption were carried out to characterise the powder physical properties. The aerosol performance of the powders was measured using an Aeroliser connected to a multiple stage liquid impinger operating at 60 L/min. The HGCP SS particles were elongated with 0.1 mu m in width but varying length of several mu m, which formed spherical agglomerates when spray dried. The particles showed the same XRD pattern and true density (1.3 g/cm(3)) as the raw material, indicating that they belonged to the same crystalline form. However, the spray dried agglomerates had a much lower tapped density (0.1 g/cm(3)) than the raw material (0.6 g/cm(3)). Compared with the powder obtained by spray drying directly from an aqueous solution, the SS powders obtained from HGCP were much less hygroscopic (0.6% versus 10% water uptake at 90% RH). The in vitro aerosol performance showed a fine particle fraction FPFloaded and FPFemitted up to 54.5 +/- 4.9% and 71.3 +/- 10.0%, respectively. In conclusion, SS powder with suitable physical and aerosol properties can be obtained through antisolvent HGCP followed by spray drying. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:93 / 98
页数:6
相关论文
共 12 条
[1]
Influence of mechanical activation on the physical stability of salbutamol sulphate [J].
Brodka-Pfeiffer, K ;
Langguth, P ;
Grass, P ;
Häusler, H .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2003, 56 (03) :393-400
[2]
Chan HK, 2003, EXPERT OPIN THER PAT, V13, P1333, DOI 10.1517/eotp.13.9.1333.22942
[3]
PRODUCTION OF SPRAY-DRIED SALBUTAMOL SULFATE FOR USE IN DRY POWDER AEROSOL FORMULATION [J].
CHAWLA, A ;
TAYLOR, KMG ;
NEWTON, JM ;
JOHNSON, MCR .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1994, 108 (03) :233-240
[4]
Feasibility of preparing nanodrugs by high-gravity reactive precipitation [J].
Chen, JF ;
Zhou, MY ;
Shao, L ;
Wang, YY ;
Yun, J ;
Chew, NYK ;
Chan, HK .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 269 (01) :267-274
[5]
Synthesis of nanoparticles with novel technology: High-gravity reactive precipitation [J].
Chen, JF ;
Wang, YH ;
Guo, F ;
Wang, XM ;
Zheng, C .
INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCH, 2000, 39 (04) :948-954
[6]
Influence of particle size, air flow, and inhaler device on the dispersion of mannitol powders as aerosols [J].
Chew, NYK ;
Chan, HK .
PHARMACEUTICAL RESEARCH, 1999, 16 (07) :1098-1103
[7]
How much particle surface corrugation is sufficient to improve aerosol performance of powders? [J].
Chew, NYK ;
Tang, P ;
Chan, HK ;
Raper, JA .
PHARMACEUTICAL RESEARCH, 2005, 22 (01) :148-152
[8]
Influence of air flow on the performance of a dry powder inhaler using computational and experimental analyses [J].
Coates, MS ;
Chan, HK ;
Fletcher, DF ;
Raper, JA .
PHARMACEUTICAL RESEARCH, 2005, 22 (09) :1445-1453
[9]
A study of the crystallisation of amorphous salbutamol sulphate using water vapour sorption and near infrared spectroscopy [J].
Columbano, A ;
Buckton, G ;
Wikeley, P .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 237 (1-2) :171-178
[10]
GONDA I, 2004, DRUGS PHARM SCI, V134, P65